Skip to content

13F-HR/A filed by Defilade Capital Management, L.P.

Defilade Capital Management, L.P. filed this 13F-HR/A for the quarter ended 2026-03-31, filed 2026-06-12, with 31 holding rows worth $712,175,993.

Accession
0002088557-26-000006
Filed
2026-06-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2026

A holdings report, amendment of type restatement, 31 entries on the cover page, a total value of $712,175,993 stated on the cover page (in dollars after the unit check, H1), rows summing to $712,175,993 with VALUE read as dollars as filed, 13F file number 028-26338. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ZIMMER BIOMET HOLDINGS INC COM98956P102Stock579,161$52,367,738dollars as filed
SCHEIN HENRY INC806407102COM624,037$45,991,527dollars as filed
BECTON DICKINSON & CO075887109COM279,210$43,900,188dollars as filed
Pfizer Inc.717081103COM1,464,129$41,112,742dollars as filed
DEXCOM INC COM252131107Stock538,762$33,834,254dollars as filed
ICU MED INC44930G107COM254,291$32,841,683dollars as filed
INSMED INC COM PAR $.01457669307Stock194,909$31,871,520dollars as filed
Intuitive Surgical,Inc.46120E602COM67,681$31,200,264dollars as filed
REVOLUTION MEDICINES INC COM76155X100Stock315,972$30,728,277dollars as filed
GLOBUS MED INC CL A379577208Stock354,350$30,530,796dollars as filed
NEUROCRINE BIOSCIENCES INC64125C109COM209,932$27,656,442dollars as filed
DENALI THERAPEUTICS INC COM24823R105Stock1,359,969$26,111,405dollars as filed
PTC THERAPEUTICS INC69366J200COM376,165$25,628,121dollars as filed
OLEMA PHARMACEUTICALS INC68062P106COM1,504,536$22,432,632dollars as filed
ELANCO ANIMAL HEALTH INC COM28414H103Stock931,121$22,281,726dollars as filed
PACS GROUP INC69380Q107COM SHS604,180$19,406,262dollars as filed
Eli Lilly and Company532457108COM20,696$19,035,560dollars as filed
LANTHEUS HLDGS INC516544103COM249,401$18,917,066dollars as filed
INTEGER HLDGS CORP45826H109COM213,027$18,746,376dollars as filed
BIOGEN INC COM09062X103Stock96,289$17,652,662dollars as filed
EVOMMUNE INC30054Y107COMMON STOCK678,589$15,600,761dollars as filed
TANDEM DIABETES CARE INC875372203COM NEW761,905$14,605,719dollars as filed
COGENT BIOSCIENCES INC19240Q201COM352,590$13,571,189dollars as filed
NUVALENT INC COM670703107Stock129,950$13,313,378dollars as filed
OCULAR THERAPEUTIX INC67576A100COM1,487,645$12,600,353dollars as filed
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR51,895$11,869,943dollars as filed
ALIGN TECHNOLOGY INC COM016255101Stock67,332$11,542,725dollars as filed
ELEDON PHARMACEUTICALS INC28617k101COM3,564,127$10,977,511dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM842,928$10,679,898dollars as filed
BIOHAVEN LTDG1110E107COM315,944$2,672,886dollars as filed
MEREO BIOPHARMA GROUP PLC589492107CMN7,558,756$2,494,389dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0002088557-26-000005 superseded2026-05-14acceptance time not in the bulk data set
13F-HR/A 0002088557-26-000006this filing2026-06-12acceptance time not in the bulk data set